{"symbol":"BMY","fiscalQuarter":"Q2-2014","reportDate":"2014-07-24","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q2-2014","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Up 0.28%","keyNumbers":[{"metric":"EPS","actual":"$0.48","expected":"N/A","surprise":"+7.62%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the continued strength in their pipeline.","They emphasized a commitment to innovation and addressing unmet medical needs."],"summary":"Overall, management expressed confidence in their product offerings and future growth potential. However, they did not provide specific guidance for the upcoming quarters."},"guidanceChanges":{"summary":"No guidance data is available for this quarter.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report shows a positive surprise in EPS, which contributed to a slight increase in stock price. The management's optimistic tone regarding their pipeline suggests potential for future growth, although the lack of revenue data and guidance leaves some uncertainty. Investors may view the EPS beat as a sign of resilience in the company's performance.","metaDescription":"Bristol Myers Squibb (BMY) Q2 2014 earnings: EPS beat by 7.62%. Stock up 0.28%. Full breakdown."}}